Q3 FY2026
Filed Nov 5, 2026Record Q3 2026 total revenue of $76.9 million; adjusted EPS of $0.29 above the high end of guidance; full-year adjusted net income guidance raised to $104.5 to $106.5 million
Total revenue rose 22% year over year to $76,883,335 and GAAP net income rose 105% to $14,516,582, with adjusted EBITDA of $42,306,633 (+12%). The company states that adjusted EPS exceeded the high end of its guidance ranges and that it raised full-year adjusted net income guidance. Offsetting points are the lower adjusted EBITDA margin (55.0% vs 60.2%), higher general and administrative expense, and a lower average realized gain (24% vs 37%).
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues (3Q26)GAAP | $76,883,335 | – | +22% |
| Asset management revenues (3Q26)GAAP | 821,588 | – | – |
| Asset management, related party revenues (3Q26)GAAP | 4,229,927 | – | – |
| Life solutions revenues (3Q26)GAAP | 36,963,970 | – | – |
| Life solutions, related party revenues (3Q26)GAAP | 34,310,393 | – | – |
| Technology services revenues (3Q26)GAAP | 557,457 | – | – |
| Gross profit (3Q26)GAAP | 69,103,739 | – | – |
| Cost of revenue, including stock-based compensation (3Q26)GAAP | 7,779,596 | – | – |
| Sales and marketing expense (3Q26)GAAP | 5,639,799 | – | – |
| General and administrative expense, including stock-based compensation (3Q26)GAAP | 33,616,461 | – | – |
| Depreciation and amortization expense (3Q26)GAAP | 4,117,078 | – | – |
| Total operating expenses (3Q26)GAAP | 43,373,338 | – | – |
| Operating income (3Q26)GAAP | 25,730,401 | – | – |
| Interest expense (3Q26)GAAP | (10,101,593) | – | – |
| Income tax expense (3Q26)GAAP | 4,198,327 | – | – |
| Net income (3Q26)GAAP | $14,516,582 | – | Up 105% |
| Net income margin (3Q26)GAAP | 18.9% | – | – |
| Earnings per share, basic (3Q26)GAAP | $0.15 | – | – |
| Earnings per share, diluted (3Q26)GAAP | $0.14 | – | – |
| Adjusted net income, gross (3Q26)non-GAAP | $29,389,057 | – | +24% |
| Adjusted EPS, gross, diluted (3Q26)non-GAAP | $0.29 | – | +20% |
| Adjusted EBITDA (3Q26)non-GAAP | $42,306,633 | – | +12% |
| Adjusted EBITDA margin (3Q26)non-GAAP | 55.0% | – | – |
| Annualized ROIC (3Q26)non-GAAP | 21% | – | – |
| Annualized ROE (3Q26)non-GAAP | 26% | – | +440 bps |
| Annualized turnover ratio (3Q26)other | 3.0x | – | – |
| Average realized gain (3Q26)other | 24% | – | – |
| Longevity fund inflows (3Q26)other | $452.4M | – | more than six times the prior-year period |
| Operating cash flow (nine months ended September 30, 2026)GAAP | $167.4M | – | +$185.6M |
| Total revenues (nine months ended September 30, 2026)GAAP | 209,293,613 | – | – |
| Gross profit (nine months ended September 30, 2026)GAAP | 186,142,181 | – | – |
| General and administrative expense (nine months ended September 30, 2026)GAAP | 92,444,660 | – | – |
| Operating income (nine months ended September 30, 2026)GAAP | 65,537,743 | – | – |
| Net income (nine months ended September 30, 2026)GAAP | 28,409,816 | – | – |
| Earnings per share, diluted (nine months ended September 30, 2026)GAAP | $0.28 | – | – |
| Adjusted net income, gross (nine months ended September 30, 2026)non-GAAP | $76,594,159 | – | – |
| Adjusted EPS, gross, diluted (nine months ended September 30, 2026)non-GAAP | $0.77 | – | – |
| Adjusted EBITDA (nine months ended September 30, 2026)non-GAAP | $114,903,605 | – | – |
| Adjusted EBITDA margin (nine months ended September 30, 2026)non-GAAP | 54.9% | – | – |
| Annualized ROE (nine months ended September 30, 2026)non-GAAP | 23% | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Asset managementRevenue line as printed in the statement of operations for the three months ended September 30, 2026 (prior-year figure 1,058,250). No explanation printed. | 821,588 | – | – |
| Asset management, related partyRevenue line as printed for the three months ended September 30, 2026 (prior-year figure 7,575,553). No explanation printed. | 4,229,927 | – | – |
| Life solutionsRevenue line as printed for the three months ended September 30, 2026 (prior-year figure 45,536,880). The release attributes total revenue growth of 22% to strong Life Solutions growth, but does not state a Life solutions change for this line. | 36,963,970 | – | – |
| Life solutions, related partyRevenue line as printed for the three months ended September 30, 2026 (prior-year figure 8,585,697). No explanation printed. | 34,310,393 | – | – |
| Technology servicesRevenue line as printed for the three months ended September 30, 2026 (prior-year figure 218,776). No explanation printed. | 557,457 | – | – |
FY2026 and 4Q26 (non-GAAP adjusted measures only; no GAAP outlook given) outlook
- NoteAdjusted net income (gross, non-GAAP) FY26: $104.5M to $106.5M, printed as implying 22% to 24% YoY with a midpoint of about 23%
- NoteAdjusted EPS (gross, non-GAAP) FY26: $1.05 to $1.07, based on diluted share count
- NoteAdjusted net income (gross, non-GAAP) 4Q26: $28M to $30M
- NoteAdjusted EPS (gross, non-GAAP) 4Q26: $0.28 to $0.30, printed as up to 30% YoY
Capital returns
- In August 2026 the Board authorized a $100 million share repurchase program, per the release.
- The release states that approximately $80 million of common stock has been repurchased under prior authorized programs since December 2023.
- Treasury stock at cost was $(81,915,091) at September 30, 2026 versus $(55,808,595) at December 31, 2025, with 10,344,990 shares repurchased versus 7,406,118 shares.
- The release does not print a dividend or the amount repurchased during the quarter.
What drove it
- The company attributes the 22% year-over-year total revenue increase to strong Life Solutions growth.
- Life solutions, related party revenue rose from 8,585,697 to 34,310,393 in the quarter, the largest change among the printed revenue lines.
- The company states that net income rose 105% on revenue growth and lower non-operating expense.
- Longevity fund inflows totaled $452.4 million in the third quarter, which the release describes as more than six times the prior-year period. Year-to-date inflows were approximately $997 million, compared with $604 million for all of 2025.
- The company states that the average realized gain of 24% exceeds its long-term target of 20%, reflecting origination discipline.
- The company states that the annualized turnover ratio of 3.0x is above its long-term target of 1.5x to 2.0x.
- The company states that the ABX Longevity Growth and Income Fund (ticker: ABXGX) launched in July as its first registered interval fund dedicated to the longevity asset class.
Concerns
- Adjusted EBITDA margin declined to 55.0% from 60.2%, and the release says the company maintains a high margin level while growing the business.
- General and administrative expense, including stock-based compensation, rose to 33,616,461 from 24,706,314, and sales and marketing expense rose to 5,639,799 from 3,799,884.
- Interest expense was (10,101,593) against (9,738,472) in the prior-year quarter.
- Average realized gain fell to 24% from 37%, although the company states that this exceeds its long-term target of 20%.
- The annualized ROIC is printed as 21% in both periods, but the note beside it reads +40 bps YoY. The two printed figures do not reconcile to that note, so no ROIC change is reported here.
- Adjusted figures are gross of estimated tax and exclude stock-based compensation, amortization, business acquisition and non-recurring legal costs, and unrealized investment gains and losses, as defined by the company. GAAP diluted EPS was $0.14 for the quarter.
- Net income for the quarter includes other income (expense), net of 2,463,375, which the release does not explain.
What to watch
- Whether the 4Q26 adjusted EPS range of $0.28 to $0.30 is achieved, given the printed guidance.
- Adjusted EBITDA margin trajectory, which fell year over year in the quarter and for the nine months (54.9% vs 57.5%).
- General and administrative expense growth relative to revenue growth.
- Use of the $100 million repurchase authorization and pace of repurchases.
- Longevity fund inflows and the realized gain rate against the company's stated targets.
- Debt of $405.0 million and interest expense, following the $400 million securitization.
- The reconciliation of the printed ROIC figures to the stated +40 bps change in the next filing.
Balance sheet and cash flow
- Cash and cash equivalents: $104.0 million at September 30, 2026 (balance sheet $104,031,612), versus $38,112,332 at December 31, 2025.
- Balance sheet policy assets held at fair value: $370.0 million (life settlement policies at fair value $369,978,847), versus $468,857,929 at December 31, 2025.
- Total outstanding debt, net of deferred issuance costs and discounts: $405.0 million at September 30, 2026.
- Total assets: $947,286,637 at September 30, 2026 versus $902,240,258 at December 31, 2025.
- Total stockholders' equity: $450,396,109 at September 30, 2026 versus $418,540,930 at December 31, 2025.
- Operating cash flow for the nine months ended September 30, 2026: $167.4 million, versus $(18.2) million in the prior-year period, which the company attributes to the increasing cash generation capacity of the platform as longevity fund AUM scales.
- In September 2026 the company completed a $400 million securitization collateralized by a diversified portfolio of life insurance policies. The notes received an investment-grade rating from a third-party rating agency and the offering was oversubscribed and upsized, per the release.
Analysis
Abacus reported third-quarter 2026 total revenues of $76,883,335, up 22% from $62,975,156 in the prior-year quarter. The company attributes the growth to strong Life Solutions growth. The mix shifted notably: Life solutions, related party rose from 8,585,697 to 34,310,393, while Life solutions revenue from other sources moved from 45,536,880 to 36,963,970 and asset management related party revenue fell from 7,575,553 to 4,229,927. The filing does not explain the mix shift beyond the company's general description. GAAP net income rose to $14,516,582 from $7,075,348, which the company says reflects revenue growth and lower non-operating expense. GAAP diluted EPS was $0.14 against $0.07.
On a non-GAAP basis, adjusted net income (gross) was $29,389,057 (+24%) and adjusted EPS (gross, diluted) was $0.29 (+20%). Adjusted EBITDA was $42,306,633 (+12%). The company states that adjusted EPS exceeded the high end of its guidance ranges, but the prior outlook was not supplied with this filing, so that comparison is not verified here. The adjusted EBITDA margin was 55.0% against 60.2%, and general and administrative expense grew faster than revenue based on the printed figures. Operating income was 25,730,401 against 22,413,178 in the prior-year quarter.
Capital allocation was active. The company reported longevity fund inflows of $452.4 million in the quarter, year-to-date inflows of approximately $997 million, a $400 million securitization completed in September, the launch of an interval fund, and a $100 million repurchase authorization approved in August. Cash and cash equivalents were $104.0 million, debt net of costs was $405.0 million, and operating cash flow for the nine months was $167.4 million against $(18.2) million a year earlier.
The company raised full-year 2026 adjusted net income guidance to $104.5 to $106.5 million and projects fourth-quarter adjusted EPS (gross) of $0.28 to $0.30. The prior range is not printed in the filing, so the size of the raise cannot be quantified from the documents. The guidance covers only non-GAAP measures, and the company states it cannot provide a GAAP reconciliation for the outlook.
The read is that growth and cash generation were both reported as strong, while margin compression on adjusted EBITDA, rising G&A and interest expense, and a lower realized gain rate are the figures that deserve attention. The printed ROIC figures are inconsistent with their own change note, so that metric is reported without a change.
Management, verbatim
When insurance companies buy into a securitization of more than $400 million, that is a strong vote of confidence in the data and the underwriting behind it. When early inquiries about LifeARC represent more than $500 million of self-reported investable assets, it tells us the demand is far larger than what we started with. Both are happening at once, and we raised our outlook for the second time this year.
Jay Jackson, Chief Executive Officer
The platform is what we set out to build, and with revenue growth of at least 20% in every quarter we have reported as a public company, it is working.
Jay Jackson, Chief Executive Officer
Not in the filing
stated, not guessed- Prior-quarter (2Q26) figures for all metrics, as no prior-quarter results are printed in the filing.
- Gross margin percentage for the quarter and the nine months, which is not printed.
- Year-over-year changes for each revenue line, operating expense line and GAAP operating income, which are not printed.
- Prior-year value of longevity fund inflows for 3Q25, which is described only as more than six times and not printed as a figure.
- Prior-guidance ranges, which were not provided, so the raise and the claim that adjusted EPS exceeded guidance cannot be verified.
- Explanation for the annualized ROIC change: printed values are 21% vs 21% but the note reads +40 bps YoY.
- Quarterly amount of share repurchases and any dividend paid during the quarter.
- Quarterly operating cash flow figure, as the release presents only the nine-month figure.
- Free cash flow and capital expenditures.
- Interest rate and maturity detail for the debt balances.
- Explanation of the change in other income (expense), net (2,463,375 in 3Q26 vs (629,127) in 3Q25).
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.